EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Sotatercept in TBX4 Associated Heritable Pulmonary Arterial Hypertension: A Case Report of a Super Responder

Jop W Schneijdenberg iD, Annemien E van den Bosch iD, Miriam E Kap, Robert M Kauling iD, Prewesh P Chandoesing, Leon M van den Toorn, Bas J Mathot iD, Thomas Koudstaal iD, Karin A Boomars iD

Pulmonary Circulation · 2026-04 · 16 (2)

DOI: 10.1002/pul2.70319 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pulmonary Circulation, online erschienen am 15.05.2026. Verfasst von Jop W Schneijdenberg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Cardiovascular Institute, Thorax Center Erasmus University Medical Center Rotterdam Zuid-Holland the Netherlands. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary arterial hypertension (PAH) is a life‐threatening disease of the pulmonary arteries. Progressively increasing pulmonary artery pressure may lead to fatal failure of the right ventricle, necessitating aggressive drug treatment. Sotatercept, a novel drug for PAH‐targeted therapy, shows promising results in clinical trials. Nevertheless, efficacy in the heterogeneous PAH population and long‐term outcomes have yet to be investigated. This case report illustrates the life‐changing effects of sotatercept in a patient with heritable PAH associated with a TBX4 mutation. Our patient faced near immobility, oxygen dependency, and was listed for lung transplantation in November 2023. Following sotatercept administration from July 2024 onward, she started sporting activities and has been removed from the transplantation waiting list. Thereby, this case illustrates an exceptional response to sotatercept in a patient with TBX4‐associated heritable PAH. Positive effects persist 1 year after initiation without significant side effects.

Schlagwörter

Stichwörter der Autor:innen

TBX4 mutationpulmonary arterial hypertensionsotatercept

Autor:innen und Institutionen

  • Department of Cardiology, Cardiovascular Institute, Thorax Center Erasmus University Medical Center Rotterdam Zuid-Holland the Netherlands.
  • Department of Pulmonary Medicine, Cardiovascular Institute, Thorax Center Erasmus University Medical Center Rotterdam Zuid-Holland the Netherlands.

ORCID-Profile: Jop W Schneijdenberg, Annemien E van den Bosch, Robert M Kauling, Bas J Mathot, Thomas Koudstaal, Karin A Boomars

Zitieren

APA

Schneijdenberg, J. W., van den Bosch, A. E., Kap, M. E., Kauling, R. M., Chandoesing, P. P., van den Toorn, L. M., Mathot, B. J., Koudstaal, T., & Boomars, K. A. (2026). Sotatercept in TBX4 Associated Heritable Pulmonary Arterial Hypertension: A Case Report of a Super Responder. Pulmonary Circulation, 16(2). https://doi.org/10.1002/pul2.70319

Vancouver

Schneijdenberg JW, van den Bosch AE, Kap ME, Kauling RM, Chandoesing PP, van den Toorn LM, et al. Sotatercept in TBX4 Associated Heritable Pulmonary Arterial Hypertension: A Case Report of a Super Responder. Pulmonary Circulation. 2026;16(2). doi:10.1002/pul2.70319

BibTeX
@article{Schneijdenberg2026,
  author = {Schneijdenberg, Jop W and van den Bosch, Annemien E and Kap, Miriam E and Kauling, Robert M and Chandoesing, Prewesh P and van den Toorn, Leon M and Mathot, Bas J and Koudstaal, Thomas and Boomars, Karin A},
  title = {Sotatercept in TBX4 Associated Heritable Pulmonary Arterial Hypertension: A Case Report of a Super Responder},
  journal = {Pulmonary Circulation},
  year = {2026},
  volume = {16},
  number = {2},
  doi = {10.1002/pul2.70319}
}
Kostenlos starten →